Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Trial Profile

Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Anti GD2 CAR transduced T cells Bellicum Pharmaceuticals (Primary) ; Cyclophosphamide; Rimiducid
  • Indications Malignant melanoma; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Feb 2017 Status changed from recruiting to completed.
    • 01 Jun 2015 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018 as reported by ClinicalTrials.gov record.
    • 18 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top